US 11,737,985 B2
Formulations comprising hydralazine, prazosin, torsemide, spironolactone, and/or naltrexone and treatments using same
Salim Shah, Vienna, VA (US)
Filed by Salim Shah, Vienna, VA (US)
Filed on Apr. 19, 2021, as Appl. No. 17/234,593.
Application 17/234,593 is a continuation in part of application No. 16/786,813, filed on Feb. 10, 2020, granted, now 11,007,203.
Application 16/786,813 is a continuation in part of application No. 16/247,555, filed on Jan. 14, 2019, granted, now 10,596,119, issued on Mar. 24, 2020.
Application 16/247,555 is a continuation in part of application No. 16/184,575, filed on Nov. 8, 2018, granted, now 10,463,622, issued on Nov. 5, 2019.
Application 16/184,575 is a continuation in part of application No. 15/027,355, granted, now 10,154,963, issued on Dec. 18, 2018, previously published as PCT/US2013/077732, filed on Dec. 26, 2013.
Claims priority of provisional application 61/887,396, filed on Oct. 6, 2013.
Prior Publication US 2021/0259975 A1, Aug. 26, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/20 (2006.01); A61K 9/00 (2006.01); A61K 31/502 (2006.01); A61P 13/00 (2006.01); A61K 31/585 (2006.01); A61K 31/517 (2006.01); A61K 31/485 (2006.01); A61K 31/4468 (2006.01)
CPC A61K 9/2054 (2013.01) [A61K 9/0053 (2013.01); A61K 31/4468 (2013.01); A61K 31/485 (2013.01); A61K 31/502 (2013.01); A61K 31/517 (2013.01); A61K 31/585 (2013.01); A61P 13/00 (2018.01)] 15 Claims
 
1. An oral dosage formulation comprising: one or more active pharmaceutical ingredients (APIs); 27 wt % to 34 wt % of hydroxypropyl methyl cellulose; 25 wt % to 53 wt % of high-density microcrystalline cellulose having a particle size of 50 micrometers to 100 micrometers; and 6.5 wt % to 8 wt % of lactose monohydrate.